Lexaria Bioscience Corp.
Last updated September 27, 2026
Organization details
- Legal name
- Lexaria Bioscience Corp.
- Former names
- Lexaria Corp.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Nevada
- Headquarters city
- Kelowna
- Headquarters country
- Canada
- Fiscal year end
- August
- Ticker symbol
- LEXX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001348362
- EIN
- 20-2000871
Board of directors
-
Albert L. Reese Jr. · DirectorSince 2023
-
Baljinder Bhullar · DirectorSince 2025
-
Catherine C. Turkel · DirectorSince 2023
-
Christopher Bunka · Director · Chief Executive OfficerSince 2023
-
John Martin Docherty · Director · President & CSOSince 2023
-
Nicholas W. Baxter · DirectorSince 2023
-
Richard Christopher · Director · Chief Executive OfficerSince 2025
-
William Edward McKechnie · DirectorSince 2023
Chief executives
Christopher Bunka
· Chief Executive Officer
Dates unknown
Richard Christopher
· Chief Executive Officer
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 17, 2026 | Christopher Bunka Director | Gift | −100,000 | — | — |
| Jul 30, 2025 | Christopher Bunka Director | Open-market purchase | +11,900 | $0.91 | $10,829 |
| Jul 29, 2025 | Christopher Bunka Director | Open-market purchase | +15,600 | $0.92 | $14,352 |
| Jul 29, 2025 | William Edward McKechnie Director | Open-market purchase | +5,000 | $0.91 | $4,550 |
| Jul 29, 2025 | John Martin Docherty Director, Officer (President & CSO) | Open-market purchase | +5,376 | $0.93 | $5,000 |
| Jul 29, 2025 | Carle Vanessa Officer (Secretary) | Open-market purchase | +750 | $0.91 | $683 |
| Jul 29, 2025 | Richard Christopher Director, Officer (Chief Executive Officer) | Open-market purchase | +15,000 | $0.91 | $13,650 |
| Jan 7, 2025 | Christopher Bunka Director | Grant or award | +100,000 | — | — |
| Dec 3, 2024 | CHRISTOPHER RICHARD Officer (Chief Executive Officer) | Open-market purchase | +27,172 | $2.47 | $67,115 |
| Dec 2, 2024 | CHRISTOPHER RICHARD Officer (Chief Executive Officer) | Open-market purchase | +22,828 | $2.24 | $51,135 |
| Aug 12, 2024 | Catherine C. Turkel Director | Open-market purchase | +1,600 | $3.13 | $5,008 |
| Jul 31, 2024 | Carle Vanessa Officer (Secretary) | Open-market sale | −2,567 | $4.00 | $10,268 |
| May 14, 2024 | Carle Vanessa Officer (Secretary) | Option exercise | +2,500 | $1.15 | $2,875 |
| Feb 9, 2023 | Catherine C. Turkel Director | Open-market purchase | +1,500 | $2.84 | $4,260 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Lexaria Bioscience Corp.
Who is the CEO of Lexaria Bioscience Corp.?
Christopher Bunka is Lexaria Bioscience Corp.'s Chief Executive Officer.
How many directors are on Lexaria Bioscience Corp.'s board?
Lexaria Bioscience Corp.'s board has 8 directors: Albert L. Reese Jr., Baljinder Bhullar, Catherine C. Turkel, Christopher Bunka, John Martin Docherty, Nicholas W. Baxter, Richard Christopher and William Edward McKechnie.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="lexaria-bioscience-corp"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.